menu
    • menu
    [{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase II","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"eXIthera Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"eXIthera Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Frunexian","moa":"F11a","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by eXIthera Pharmaceutical

    Menu

    eXIthera Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Frunexian

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Cadrenal Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cadrenal Acquires eXIthera’s Factor XIa Inhibitors Portfolio

                            Details : The Acquisition enhances the Company’s pipeline by adding novel assets, including frunexian, a first-in-class, Phase 2-ready IV Factor XIa inhibitor in acute and chronic anticoagulation settings.

                            Product Name : EP-7041

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 15, 2025

                            Lead Product(s) : Frunexian

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Cadrenal Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients

                            Details : EP-7041 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombocytopenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 10, 2021

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            eXIthera Announces Publication of EP-7041 Data Demonstrating Safe Antithrombotic Activity in ECMO

                            Details : By preferentially inhibiting thrombosis but not normal hemostasis, EP-7041 holds the promise of preventing circuit and vascular thromboembolism with substantially less inhibition of the local hemostasis required for bleeding control in trauma or surgical...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed

                            eXIthera Pharmaceutical

                            U.S.A arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase I

                            Sponsor : IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects

                            Details : EP-7041 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthroplasty, Replacement, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 26, 2016

                            Lead Product(s) : EP-7041

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase I

                            Sponsor : IDT CMAX Clinical Trials | Syneos Health | CPR Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth